Literature DB >> 21917670

Scar size and characteristics assessed by CMR predict ventricular arrhythmias in ischaemic cardiomyopathy: comparison of previously validated models.

Stefan de Haan1, Thomas A Meijers, Paul Knaapen, Aernout M Beek, Albert C van Rossum, Cornelis P Allaart.   

Abstract

OBJECTIVE: Sudden cardiac death is a major cause of mortality in patients with ischaemic cardiomyopathy. Risk stratification remains challenging. Currently, there is growing interest in scar characteristic assessment as a predictor of sudden cardiac death using cardiac magnetic resonance imaging (CMR). Standard analysis methods are lacking. The present study evaluated previously validated methods of scar assessment by CMR with late gadolinium enhancement (LGE) in their ability to predict ventricular tachyarrhythmias.
METHODS: Patients with ischaemic cardiomyopathy who received an implantable cardioverter defibrillator for primary prevention and in whom a LGE-CMR was performed, were included. Scar core size, peri-infarct zone and total scar size, which is defined as the sum of the core size and peri-infarct zone, were assessed using three previously validated models, and their ability to predict ventricular tachyarrhythmias was evaluated.
RESULTS: Fifty-five patients were included (mean age 64.6 ± 10.8 years, 43 men). During a median follow-up of 2.0 years (IQR 1.0-3.0 years) 26% of patients reached the endpoint of ventricular tachyarrhythmia. All scar characteristics (ie, total scar size, scar core size and peri-infarct zone) of the three methods were predictors of the endpoint (p < 0.01). Total scar size was comparable, whereas scar core size and peri-infarct zone varied significantly between the tested models. Receiver operating characteristic curves of the different scar characteristics showed comparable areas under the curve varying from 0.721 to 0.812.
CONCLUSIONS: LGE-CMR-derived scar tissue characteristics are of predictive value for the occurrence of ventricular tachyarrhythmias in patients with ischaemic cardiomyopathy. Additional estimation of scar core size and/or peri-infarct zone does not appear to increase the diagnostic accuracy over total scar size alone.

Entities:  

Mesh:

Year:  2011        PMID: 21917670     DOI: 10.1136/heartjnl-2011-300060

Source DB:  PubMed          Journal:  Heart        ISSN: 1355-6037            Impact factor:   5.994


  29 in total

1.  Myocardial denervation coincides with scar heterogeneity in ischemic cardiomyopathy: A PET and CMR study.

Authors:  Stefan de Haan; Mischa T Rijnierse; Hendrik J Harms; Hein J Verberne; Adriaan A Lammertsma; Marc C Huisman; Albert D Windhorst; Albert C van Rossum; Cornelis P Allaart; Paul Knaapen
Journal:  J Nucl Cardiol       Date:  2015-11-09       Impact factor: 5.952

2.  Myocardial scar imaging by standard single-energy and dual-energy late enhancement CT: Comparison with pathology and electroanatomic map in an experimental chronic infarct porcine model.

Authors:  Quynh A Truong; Wai-Ee Thai; Bryan Wai; Kevin Cordaro; Teresa Cheng; Jonathan Beaudoin; Guanglei Xiong; Jim W Cheung; Robert Altman; James K Min; Jagmeet P Singh; Conor D Barrett; Stephan Danik
Journal:  J Cardiovasc Comput Tomogr       Date:  2015-03-24

3.  Impact of denervated myocardium on improving risk stratification for sudden cardiac death.

Authors:  Michael E Cain
Journal:  Trans Am Clin Climatol Assoc       Date:  2014

4.  Magnetic resonance estimates of the extent and heterogeneity of scar tissue in ICD patients with ischemic cardiomyopathy predict ventricular arrhythmia.

Authors:  Tawfiq Zeidan-Shwiri; Yuesong Yang; Ilan Lashevsky; Ehud Kadmon; Darren Kagal; Alexander Dick; Avishag Laish Farkash; Gideon Paul; Donsheng Gao; Mohammed Shurrab; David Newman; Graham Wright; Eugene Crystal
Journal:  Heart Rhythm       Date:  2015-01-09       Impact factor: 6.343

Review 5.  Structural and Physiological Imaging to Predict the Risk of Lethal Ventricular Arrhythmias and Sudden Death.

Authors:  Saurabh Malhotra; John M Canty
Journal:  JACC Cardiovasc Imaging       Date:  2019-10

6.  Cardiovascular Magnetic Resonance to Predict Appropriate Implantable Cardioverter Defibrillator Therapy in Ischemic and Nonischemic Cardiomyopathy Patients Using Late Gadolinium Enhancement Border Zone: Comparison of Four Analysis Methods.

Authors:  Robert Jablonowski; Uzma Chaudhry; Jesper van der Pals; Henrik Engblom; Håkan Arheden; Einar Heiberg; Katherine C Wu; Rasmus Borgquist; Marcus Carlsson
Journal:  Circ Cardiovasc Imaging       Date:  2017-09       Impact factor: 7.792

7.  Life-Threatening Ventricular Arrhythmias: Current Role of Imaging in Diagnosis and Risk Assessment.

Authors:  Saurabh Malhotra; John M Canty
Journal:  J Nucl Cardiol       Date:  2016-01-15       Impact factor: 5.952

8.  Regional myocardial sympathetic denervation predicts the risk of sudden cardiac arrest in ischemic cardiomyopathy.

Authors:  James A Fallavollita; Brendan M Heavey; Andrew J Luisi; Suzanne M Michalek; Sunil Baldwa; Terry L Mashtare; Alan D Hutson; Robert A Dekemp; Michael S Haka; Munawwar Sajjad; Thomas R Cimato; Anne B Curtis; Michael E Cain; John M Canty
Journal:  J Am Coll Cardiol       Date:  2013-09-25       Impact factor: 24.094

9.  Screening for Cardiac Magnetic Resonance Scar Features by 12-Lead ECG, in Patients with Preserved Ejection Fraction.

Authors:  Nathan Mewton; David G Strauss; Patricia Rizzi; Richard L Verrier; Chia Ying Liu; Larisa G Tereshchenko; Bruce Nearing; Gustavo J Volpe; Francis E Marchlinski; John Moxley; Tony Killian; Katherine C Wu; Peter Spooner; João A C Lima
Journal:  Ann Noninvasive Electrocardiol       Date:  2016-01       Impact factor: 1.468

10.  Intracoronary cardiosphere-derived cells for heart regeneration after myocardial infarction (CADUCEUS): a prospective, randomised phase 1 trial.

Authors:  Raj R Makkar; Rachel R Smith; Ke Cheng; Konstantinos Malliaras; Louise Ej Thomson; Daniel Berman; Lawrence Sc Czer; Linda Marbán; Adam Mendizabal; Peter V Johnston; Stuart D Russell; Karl H Schuleri; Albert C Lardo; Gary Gerstenblith; Eduardo Marbán
Journal:  Lancet       Date:  2012-02-14       Impact factor: 79.321

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.